Carla J. Chibwesha

Carla J. Chibwesha

Auto-generated profile, based on publicly available information

Carla J. Chibwesha

University of North Carolina at Chapel Hill, Department of Obstetrics and Gynecology, School of Medicine, Chapel Hill, North Carolina, United States of America

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2022 in BMJ
Verified
Journal Article
Closed access
PDF file
LRLisa Rahangdale
Lisa Rahangdale
CMChemtai Mungo
Chemtai Mungo
SOSiobhan O’cOnnor
Siobhan O’cOnnor
CCCarla J Chibwesha
Carla J Chibwesha
NBNoel Brewer
Noel Brewer
Persistent human papillomavirus infection is the central cause of cervical cancer, the leading cause of cancer death among women worldwide. Clear evidence from both randomized trials and population based studies shows that vaccination against human papillomavirus reduces the incidence of cervical pre-cancer. These data suggest that the vaccine reduces the incidence of cervical cancer. However, human papillomavirus vaccine coverage is inadequate in all countries, especially in low and middle income countries where disease burden is highest. Supply side strategies to improve coverage include increasing the availability of low cost vaccines, school located delivery, single dose vaccine schedules, and development of vaccines that do not need refrigeration. Demand side strategies include enhancing provider recommendations, correcting misinformation, and public awareness campaigns. The near elimination of cervical cancer is achievable through increased uptake of human papillomavirus vaccination and efforts to increase screening for cervical cancer, especially when enacted to reduce disparities in across the world.

1 September 2016 in International Journal of Gynecology & Obstetrics
Verified
Journal Article
Closed access
CCCarla J. Chibwesha
Carla J. Chibwesha
AZArianna Zanolini
Arianna Zanolini
MSMarcela Smid
Marcela Smid
BVBellington Vwalika
Bellington Vwalika
MKMargaret Phiri Kasaro
Margaret Phiri Kasaro
ESElizabeth M. Stringer
Elizabeth M. Stringer

1 July 2016 in Journal of Lower Genital Tract Disease
Verified
Journal Article
Closed access
CCCarla J. Chibwesha
Carla J. Chibwesha
BFBrigitte Msw Frett
Brigitte Msw Frett
KKKatundu Msc Katundu
Katundu Msc Katundu
ABAllen C. Bateman
Allen C. Bateman
ASAaron Mmed Shibemba
Aaron Mmed Shibemba
GPGroesbeck P. Parham
Groesbeck P. Parham
Objectives: We sought to determine the clinical performance of visual inspection with acetic acid (VIA), digital cervicography (DC), Xpert human papillomavirus (HPV), and OncoE6 for cervical cancer screening in an HIV-infected population. Materials and Methods: HIV-infected women 18 years or older were included in this cross-sectional validation study conducted in Lusaka, Zambia. The screening tests were compared against a histological gold standard. We calculated sensitivity, specificity, positive and negative predictive values, positive and negative likelihood ratios, and odds ratios using cervical intraepithelial neoplasia grade 2 or worse (CIN 2+) and grade 3 or worse (CIN 3+) thresholds. Results: Between January and June 2015, a total of 200 women were enrolled. Fifteen percent were screen positive by VIA, 20% by DC, 47% by Xpert HPV, and 6% by OncoE6. Using a CIN 2+ threshold, the sensitivity and specificity of VIA were 48% (95% CI = 30%–67%) and 92% (95% CI = 86%–95%), respectively. Similarly, the sensitivity and specificity of DC were 59% (95% CI = 41%–76%) and 88% (95% CI = 82%–93%), respectively. The sensitivity and specificity of Xpert HPV were 88% (95% CI = 71%–97%) and 60% (95% CI = 52%–68%), respectively. Finally, the sensitivity and specificity of OncoE6 were 31% (95% CI = 16%–50%) and 99% (95% CI = 97%–100%), respectively. Conclusions: VIA and DC displayed moderate sensitivity and high specificity. Xpert HPV performed equivalently to currently approved HPV DNA tests, with high sensitivity and moderate specificity. OncoE6 displayed excellent specificity but low sensitivity. These results confirm an important role for VIA, DC, and Xpert HPV in screen-and-treat cervical cancer prevention in low- and middle-income countries, such as Zambia.

10 January 2019 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
BCBenjamin H. Chi
Benjamin H. Chi
JBJose Belizan
Jose Belizan
MBMagaly M. Blas
Magaly M. Blas
ACAlice Chuang
Alice Chuang
MWMichael David Wilson
Michael David Wilson
TRTony Raj
Tony Raj
A growing number of low- and middle-income country (LMIC) institutions have developed and implemented formal programs to support mentorship. Although the individual-level benefits of mentorship are well established, such activities can also sustainably build institutional capacity, bridge inequities in health care, and catalyze scientific advancement. To date, however, evaluation of these programs remains limited, representing an important gap in our understanding about the impact of mentoring. Without rigorous and ongoing evaluation, there may be missed opportunities for identifying best practices, iteratively improving program activities, and demonstrating the returns on investment in mentorship. In this report, we propose a framework for evaluating mentorship programs in LMIC settings where resources may be constrained. We identify six domains: 1) mentor–mentee relationship, 2) career guidance, 3) academic productivity, 4) networking, 5) wellness, and 6) organizational capacity. Within each, we describe specific metrics and how they may be considered as part of evaluation plans. We emphasize the role of measurement and evaluation at the institutional level, so that programs may enhance their mentoring capacity and optimize the management of their resources. Although we advocate for a comprehensive approach to evaluation, we recognize that—depending on stage and relative maturity—some domains may be prioritized to address short- and medium-term program goals.

1 October 2018 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Open access
NCNicole G. Campos
Nicole G. Campos
NLNaomi Lince-Deroche
Naomi Lince-Deroche
CCCarla J. Chibwesha
Carla J. Chibwesha
CFCynthia Firnhaber
Cynthia Firnhaber
JSJennifer S. Smith
Jennifer S. Smith
JKJane J. Kim
Jane J. Kim
Background: Women with HIV face an increased risk of human papillomavirus (HPV) acquisition and persistence, cervical intraepithelial neoplasia, and invasive cervical cancer. Our objective was to determine the cost-effectiveness of different cervical cancer screening strategies among women with HIV in South Africa.Methods: We modified a mathematical model of HPV infection and cervical disease to reflect coinfection with HIV. The model was calibrated to epidemiologic data from HIV-infected women in South Africa. Clinical and economic data were drawn from in-country data sources. The model was used to project reductions in the lifetime risk of cervical cancer and incremental cost-effectiveness ratios (ICERs) of Pap and HPV DNA screening and management algorithms beginning at HIV diagnosis, at 1-, 2-, or 3-year intervals. Strategies with an ICER below South Africa's 2016 per capita gross domestic product (US$5270) were considered “cost-effective.”Results: HPV testing followed by treatment (test-and-treat) at 2-year intervals was the most effective strategy that was also cost-effective, reducing lifetime cancer risk by 56.6% with an ICER of US$3010 per year of life saved. Other cost-effective strategies included Pap (referral threshold: HSIL+) at 1-, 2-, and 3-year intervals, and HPV test-and-treat at 3-year intervals. Pap (ASCUS+), HPV testing with 16/18 genotyping, and HPV testing with Pap or visual triage of HPV-positive women were less effective and more costly than alternatives.Conclusions: Considering per capita gross domestic product as the benchmark for cost-effectiveness, HPV test-and-treat is optimal in South Africa. At lower cost-effectiveness benchmarks, Pap (HSIL+) would be optimal.

1 December 2016 in Papillomavirus Research
Verified
Journal Article
Open access
ZMZizipho Z.A. Mbulawa
Zizipho Z.A. Mbulawa
TWTimothy J. Wilkin
Timothy J. Wilkin
BGBridgette Goeieman
Bridgette Goeieman
ASAvril Swarts
Avril Swarts
SWSophie Williams
Sophie Williams
CFCynthia Firnhaber
Cynthia Firnhaber
This study investigated the performance of Cepheid Xpert human papillomavirus (HPV) assay in South African human immunodeficiency virus (HIV)-infected women and compared its performance with that of hybrid capture-2 (hc2). Stored cervical specimens from HIV-infected women that had previously been tested using hc2 were tested using Xpert. The overall HR-HPV prevalence was found to be 62.0% (720/1161) by Xpert and 61.2% (711/1161) by hc2. 13.6% (158/1161) were HPV16 positive, 18.8% (218/1161) were HPV18/45, 37.3% (434/1161) were HPV31/33/35/52/58, 12.7% (147/1161) were HPV51/59 and 23.3% (270/1161) were HPV39/68/56/66. Overall agreement with hc2 was 90%; Cohen's kappa was 0.78 (95% CI 0.74-0.82) indicating substantial agreement. Detection of HPV16, HPV18/45, and HPV31/33/35/52/58 were independently associated with cervical intraepithelial neoplasia (CIN)-2+ (P<0.0001 for each); while HPV51/59 and HPV39/68/56/66 were not. Women infected with HPV16, HPV18/45 or HPV31/33/35/52/58 were found to have significantly higher amounts of HPV DNA detected for those with CIN2+ compared to those without CIN2+, P<0.0001 for each. Xpert and hc2 were similarly sensitive (88.3% and 91.5%, respectively) and specific (48.4% and 51.0%) for CIN2+ and CIN3 (sensitivity: 95.8% and 97.9%; specificity: 41.4% and 42.8%). Xpert is a promising screening test in HIV-infected women that performs similarly to hc2.